Emergent biosolution stock.

Key Points. Emergent BioSolutions saw its stock plummet due to a bunch of problems in 2021. Its pipeline is unimpressive, and its services revenue isn't anything special. If its sales of over-the ...Emergent Biosolutions (EBS) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of $0.32. This compares to earnings of $4.50 per share a year ago.30 thg 4, 2021 ... Biotech firm Emergent BioSolutions is under scrutiny after quality control issues forced millions of potential COVID-19 vaccines to be ...Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use. February 15, 2023 17:19 ET ...

11 thg 8, 2023 ... Why Emergent Biosolutions Inc's (EBS) Stock Is Down 4.20% ... One of the most dreaded feelings for an investor is when the stock they just bought ...Emergent BioSolutions Contacts: Media: Matt Hartwig Senior Director, Media Relations 240-760-0551 [email protected] Investors: Rich Lindahl Executive Vice President & Chief Financial Officer 240-631-3360 [email protected]. Source: Emergent BioSolutions132. Last summer, investors flocked to the biotech company Emergent BioSolutions. The host of CNBC’s “Mad Money,” Jim Cramer, gushed about the Maryland business, which had secured a ...

Emergent Biosolutions stock is currently +15.47% from its 52-week low of $1.81, and -87.46% from its 52-week high of $16.66. As of Nov 20, 2023, there are 51.81M EBS shares outstanding. The market value of EBS is $108.28M. In the past 24 hours, 844,197 EBS shares were traded.Mar 29, 2023 · Investors ran up stock in Gaithersburg, Maryland-based Emergent BioSolutions Wednesday, after the U.S. Food and Drug Administration approved opioid overdose treatment Narcan for over-the-counter ...

MORE: In wake of Emergent BioSolutions' vaccine problems, CEO's stock trades come into focus The recent cross-contamination at the Baltimore plant is not the first time Emergent has had to answer ...Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Earnings: 26-Feb (Est.) Company Event: 1-Jul. EBS Stock Summary and Trading Ideas (Emergent Biosolutions ...Emergent Biosolutions Inc. analyst ratings, historical stock prices, earnings estimates & actuals. EBS updated stock price target summary.Discover historical prices for EBS stock on Yahoo Finance. View daily, weekly or monthly format back to when Emergent BioSolutions Inc. stock was issued.

Apr 22, 2021 · The stock price of Emergent Biosolutions, a biopharmaceutical company focused on vaccines and antibody therapeutics for infectious diseases, and opioid overdoses, has seen a 17% drop over the last ...

Contract healthcare manufacturing company Emergent BioSolutions ( EBS -0.48%) was looking a bit under the weather as far as its stock was concerned on Tuesday. The company's share price plummeted ...

Emergent Biosolutions Inc (EBS) stock is trading at $8.58 as of 11:21 AM on Monday, Mar 27, an increase of $0.48, or 5.93% from the previous closing price of $8.10. The stock has traded between $8.24 and $8.62 so far today. Volume today is light. So far 425,778 shares have traded compared to average volume of 1,546,652 shares.What happened. Shares of Emergent BioSolutions ( EBS -0.96%) were jumping 12% as of 11:09 a.m. ET on Monday. The big gain was due to increased concerns about the spread of monkeypox. Emergent ...2.14. Exchange. NYSE. 12/01/23 4:10 pm EST. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website contains information about Emergent …On average, analysts give Emergent Biosolutions Inc a Hold rating. The average price target is $28.4, which means analysts expect the stock to climb by 231.00% over the next twelve months. That average ranking earns Emergent Biosolutions Inc an Analyst Rating of 3, which is better than 3% of stocks based on data compiled by InvestorsObserver.Emergent Biosolutions (NYSE: EBS) is owned by 79.75% institutional shareholders, 93.92% Emergent Biosolutions insiders, and 0.00% retail investors. Fuad Elhibri is the largest individual Emergent Biosolutions shareholder, owning 25.73M shares representing 49.67% of the company. Fuad Elhibri's Emergent Biosolutions shares are currently …Emergent Biosolutions Inc. analyst ratings, historical stock prices, ... Actuals & Estimates Emergent Biosolutions Inc. Quarterly; Annual; Actual Analyst Range Consensus. 2.00 0.00-2.00. Actual-0.31 .So what. ACAM2000 already ranks as one of Emergent BioSolutions' top products. The smallpox vaccine raked in $206.5 million in sales last year, accounting for 11.5% of the company's total revenue.

10 stocks we like better than Emergent BioSolutions When o ur analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock ...Stock Quote & Chart. Data Provided by Refinitiv. Minimum 15 minutes delayed. The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts.Get the latest Emergent Biosolutions Inc. (EBS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.What happened. Shares of Emergent BioSolutions ( EBS -1.91%) are sinking today, down 11.8% as of 11:27 a.m. ET. The decline came after the company announced its second-quarter financial results ...Latest Emergent Biosolutions Inc ( EBS) Stock News. As of September 03, 2021, Emergent Biosolutions Inc had a $3.4 billion market capitalization, compared to the Pharmaceuticals median of $182.9 million, Emergent Biosolutions Inc’s stock is down 31.2% in 2021, down 3.4% in the previous five trading days and down 40.9% in the past …Emergent Biosolutions stock is currently +15.47% from its 52-week low of $1.81, and -87.46% from its 52-week high of $16.66. As of Nov 20, 2023, there are 51.81M EBS shares outstanding. The market value of EBS is $108.28M. In the past 24 hours, 844,197 EBS shares were traded.

Emergent Biosolutions shares outstanding from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including ...Oct 2, 2023 · Emergent BioSolutions. GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of ...

Emergent BioSolutions. Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101M. Updates FY 2023 guidance and provides ...What happened. Emergent BioSolutions probably wishes it had stayed in bed on Tuesday. The company's stock declined by nearly 12% that day, following its release of quarterly results that fell well ...Oct 2, 2023 · Emergent BioSolutions. GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of ... Crypto Sectors Contact Us U.S. markets closed +13.44 -23.27 Russell 2000 +11.00 Emergent BioSolutions Inc. (EBS) NYSE - Nasdaq Real Time Price. Currency in USD Follow 2W 10W 9M 2.1500 +0.1400...Contract drugmaker Emergent BioSolutions Inc said on Thursday it is aiming to price the over-the-counter (OTC) version of its opioid overdose reversal drug Narcan at around $50 per carton.Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently up 27.51% so far this month. During the month of April, Emergent Biosolutions Inc’s stock price has reached a high of $13.67 and a low of $9.47. Over the last year, Emergent Biosolutions Inc has hit prices as high as $43.33 and as low as $7.74.Emergent BioSolutions Inc. has rescheduled its conference call to discuss the financial results for the third quarter of 2023, recent business deve...Is Emergent Biosolutions Inc stock A Buy? Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current ...

Jun 27, 2023 · Contract healthcare manufacturing company Emergent BioSolutions ( EBS -0.48%) was looking a bit under the weather as far as its stock was concerned on Tuesday. The company's share price plummeted ...

Based on short-term price targets offered by two analysts, the average price target for Emergent Biosolutions comes to $13.50. The forecasts range from a low of $5.00 to a high of $22.00. The ...

Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023. GAITHERSBURG, Md. , Oct. 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023 , at 5:00 pm eastern time to discuss the financial results for the. Sep 7, 2023 · Emergent Biosolutions is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Axsome Therapeutics (AXSM), a stock from the same industry, has gained 16.4%. Benchmark upgraded Emergent BioSolutions Inc (NYSE:EBS) from Hold To Buy with a price target of $22 on the positive FDA and Narcan market news.; Related: FDA Approves First OTC Naloxone Nasal ...Mar 27, 2023 · Emergent Biosolutions Inc Stock Price History. Emergent Biosolutions Inc’s price is currently down 28.43% so far this month. During the month of March, Emergent Biosolutions Inc’s stock price has reached a high of $12.54 and a low of $7.74. Over the last year, Emergent Biosolutions Inc has hit prices as high as $45.14 and as low as $7.74. 30 thg 4, 2021 ... Biotech firm Emergent BioSolutions is under scrutiny after quality control issues forced millions of potential COVID-19 vaccines to be ...EBS Price Action: Emergent Biosolutions has a 52-week high of $45.02 and a 52-week low of $7.74. The stock was up 18.9% at $10.59 at time of publication, according to Benzinga Pro. Photo: courtesy ...Access to Narcan, a lifesaving drug that reverses overdoses, has been limited by Emergent BioSolutions’ hunt for profits, including a five-year delay in bringing it over the counter.Emergent BioSolutions. GAITHERSBURG, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a sharpened strategic focus on protecting and enhancing life through ...Emergent BioSolutions Inc. 2.15. Delayed Data. As of Nov 29. +0.14 / +6.97%. Today’s Change. 1.81. Today ||| 52-Week Range. 16.66.11 thg 8, 2023 ... Why Emergent Biosolutions Inc's (EBS) Stock Is Down 4.20% ... One of the most dreaded feelings for an investor is when the stock they just bought ...

Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021. Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and ...EBS earnings call for the period ending September 30, 2023. Image source: The Motley Fool. Emergent BioSolutions ( EBS 11.68%) Q3 2023 Earnings Call. Nov 08, 2023, 5:00 p.m. ET. Emergent BioSolutions reinstated with an Underweight at JPMorgan November 20, 2023TipRanks. Mixed Financial Outlook for Emergent Biosolutions: Strong Narcan Sales Offset by Lowered Guidance and ...May 10, 2022. WASHINGTON — Emergent BioSolutions, a longtime government contractor hired to produce hundreds of millions of coronavirus vaccine doses, hid evidence of quality control problems ...Instagram:https://instagram. betr home stocktd scottradestock softwaresex dividend dates calendar EBS Price Action: Emergent Biosolutions has a 52-week high of $45.02 and a 52-week low of $7.74. The stock was up 18.9% at $10.59 at time of publication, according to Benzinga Pro. Photo: courtesy ... gh power stockpkg quote Emergent BioSolutions stock has received a consensus rating of buy. The average rating score is and is based on 5 buy ratings, 3 hold ratings, and 1 sell ratings. what's the best forex broker 2011. The Investor Relations website contains information about Emergent BioSolutions Inc.'s business for stockholders, potential investors, and financial analysts.Emergent BioSolutions' stock has been hit with negative news in recent months. The company's future and valuation appear bright and strong, creating a buying opportunity.